Namodenoson’s Compassionate Use For Pancreatic Cancer Sought By US Medical Centers
Can-Fite BioPharma announced that major U.S. medical centers are requesting FDA compassionate use approval for Namodenoson, its pancreatic cancer...
Alector Announces Phase 2 Trial Completion for Early Alzheimer’s Disease
Alector and GSK have completed enrollment in their Phase 2 PROGRESS-AD trial, evaluating AL101/GSK4527226 for early-stage Alzheimer’s diseaseAlzheimer’s disease....
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130
uniQure’s AMT-130 gene therapy for Huntington’s disease has received Breakthrough Therapy designation from the FDA, adding to its existing...
Nurix’s Novel IRAK4 Degrader, GS-6791/NX-0479, Gets FDA Clearance
Nurix Therapeutics announced FDA clearance of the Investigational New Drug (IND) application for GS-6791/NX-0479, an IRAK4 degrader. This allows...
Tonix TNX-102 SL: Innovating Fibromyalgia Treatment in Development
In this interview, we sit with Seth Lederman, CEO of Tonix Pharmaceuticals, about their new drug in development for...
Breakthroughs in Post-Polio Syndrome Treatment: Grifols’ Innovative Approach
In this discussion, Dr. Jörg Schüttrumpf, Chief Scientific Innovation Officer at Grifols, delves into the promising results of their...
Durect Transforming AH Treatment with Larsucosterol’s Promise
In this interview, Jim Brown, CEO of Durect Corporation, shared insights into the treatment of Alcohol-Associated Hepatitis (AH) with...
Promising Interim Results from Phase III Agalsidase Beta Study for Fabry Disease
Biosidus, an Argentinian biotechnology company, announced positive interim Phase III trial results for its agalsidase beta biosimilar for Fabry...
Sabin Launches Marburg Vaccine Trial in US
The Sabin Vaccine Institute initiated a Phase 2 clinical trial of its Marburg vaccine candidate in the United States,...
Sonnet Releases Positive Safety Data for SON-1010 in Phase 1b/2a
Sonnet BioTherapeutics announced positive safety data for SON-1010 (IL12-FHAB) at the highest dose combined with atezolizumab in a Phase...